Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
How are you deciding between T-DXd/pertuzumab and HP/tucatinib in patients with metastatic HER2+ breast cancer?
Related Questions
How will you sequence Dato-DXd among available therapies for HR positive, HER2-0 metastatic breast cancer?
How would you approach systemic treatment of oligometastatic recurrence following surgical removal of the single area of metastases in a patient with ER+ (20-30%), PR-negative, HER2-negative breast cancer?
Do you continue ovarian suppression for metastatic hormone-positive breast cancer patients who are premenopausal, regardless of line of therapy?
How do you manage a symptomatic primary breast tumor in a patient with metastatic disease?
How do the findings from the INAVO120 trial influence your decision-making process for selecting subsequent lines of therapy in patients who have relapsed after adjuvant CDK4/6 inhibition?
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
For an elderly woman with de novo metastatic HER2+ breast cancer with lung and brain mets, how would you approach her treatment, especially now with data from DESTINY-Breast 09 data?
In what clinical scenarios, if any, would you consider using sacituzumab govitecan prior to trastuzumab deruxtecan for HR+/HER2- metastatic breast cancer treatment?
For metastatic ER+ HER2-negative breast cancer treatment, how do you select between imlunestrant (plus or minus abemaciclib) and elacestrant for those with an ESR1 mutation and progressed on AI and CDK 4/6 inhibitor?
What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?
